# Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee

> **NCT03062787** · NA · COMPLETED · sponsor: **Pharmascience Inc.** · enrollment: 60 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DEVICE:** Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)
- **DEVICE:** Monovisc® (Sodium hyaluronate)

## Key facts

- **NCT ID:** NCT03062787
- **Lead sponsor:** Pharmascience Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-05
- **Primary completion:** 2017-10-25
- **Final completion:** 2017-10-25
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062787, "Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03062787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*